InvestorsHub Logo
Followers 16
Posts 1898
Boards Moderated 0
Alias Born 05/12/2016

Re: Geo2014 post# 42270

Wednesday, 08/17/2016 11:30:36 AM

Wednesday, August 17, 2016 11:30:36 AM

Post# of 140475
If ISRG was to buy Titan, we'd be getting a 1500:1 reverse split! I like the idea of staying independent to the extent possible and reaping the larger rewards - being a piece of a giant like JnJ would be the ultimate in dilution. How much could a little startup impact the bottom line of a company which has $30B in cash on hand? Getting into something small for maximum reward was a big part of the initial allure of Titan stock for me 5+ years ago.

As far as 1.0 vs. 2.0, I'm not sure there is a difference except with the regulatory filings. Most of the hardware should be in place in 1.0. I was under the impression that the ongoing development was mostly to meet the new Human Factors guidelines, otherwise we would have been filing NLT Q4 2016 (which starts in 6 weeks). But because of the new HF guidelines, the development requires completion. Can someone who works in surgery provide ideas on how different the hardware would need to be in order to be used for multiple additional indications? (Not my area of expertise.) In other words, how much additional development might be needed to transition from a 1.0 to a 2.0 system? The hardware I've seen in videos looked capable of doing a lot of different things.

Even if it required some hardware mods for additional procedures, that could be a freebie thrown in with purchase of the 1.0 system. Worth it to get these in the field and initiate revenue flow, IMO.